September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Neutrophil to Lymphocyte Ratio in Patients with Primary Uveal Melanoma
Author Affiliations & Notes
  • Saipriya Iyer
    Memorial Sloan Kettering Cancer Center, Manhattan, New York, United States
  • Christopher A. Barker
    Memorial Sloan Kettering Cancer Center, Manhattan, New York, United States
  • David H Abramson
    Memorial Sloan Kettering Cancer Center, Manhattan, New York, United States
  • Brian P Marr
    Memorial Sloan Kettering Cancer Center, Manhattan, New York, United States
  • Jasmine H Francis
    Memorial Sloan Kettering Cancer Center, Manhattan, New York, United States
  • Footnotes
    Commercial Relationships   Saipriya Iyer, None; Christopher Barker, None; David Abramson, None; Brian Marr, None; Jasmine Francis, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5888. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Saipriya Iyer, Christopher A. Barker, David H Abramson, Brian P Marr, Jasmine H Francis; Neutrophil to Lymphocyte Ratio in Patients with Primary Uveal Melanoma. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5888.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Although only 2-3% of uveal melanoma patients have clinically evident metastatic disease at the time of their primary diagnosis, 50% of patients ultimately develop metastatic disease. As a result, prognostication, ideally through non-invasive methods, is particularly pertinent for this disease. High neutrophil-to-lymphocyte ratio (NLR) has been observed to correlate directly with poor prognosis in a number of cancers and other medical conditions. However, the use of the NLR metric is understudied in patients with primary uveal melanoma. The aim of this study was to determine if NLR correlated with overall survival (OS) as well as metastasis free survival (DFS).

Methods : A retrospective review was conducted from April 2004 to June 2015. A total 372 primary uveal melanoma cases had available laboratory values and were included in the study: 89 patients had primary enucleation and 283 received plaque brachytherapy. Neutrophil-to-lymphocyte ratio was obtained at the time of presurgical testing for enucleation or brachytherapy surgery. All-cause mortality was deemed an event for overall survival. Kaplan-Meier (KM) estimates were generated for overall survival and metastasis-free survival and the Log rank test used for curve comparison.

Results : The mean calculated NLR was 2.8, and the mean follow-up was 40.6 months. The 4-year KM estimate for overall survival was significantly worse (p=0.003) for patients with NLR > 2.8 (75.5% 95%CI 66-82.7) compared with patients with NLR < 2.8 (90.3% 95%CI 81.3-95.1). The 4-year KM estimate for metastasis-free survival was not significantly different between patients with NLR > 2.8 (86.1% 95%CI 79.4-90.8) or NLR < 2.8 (82.8 95%CI 73.9-88.9).

Conclusions : Neutrophil-to-lymphocyte ratio may have an association with prognosis in patients with uveal melanoma.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×